Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease

Clin Ther. 1995 May-Jun;17(3):572-80. doi: 10.1016/0149-2918(95)80123-5.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Letter

MeSH terms

  • Coronary Disease / prevention & control*
  • Cost-Benefit Analysis
  • Enzyme Inhibitors / economics*
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Hypolipidemic Agents / economics*
  • Hypolipidemic Agents / therapeutic use*

Substances

  • Enzyme Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents